Related Experiment Videos
Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma
S Junnikkala1, J Hakulinen, S Meri
1Department of Bacteriology, University of Helsinki, Finland.
Abstract:
Major problems in the immunotherapy of human tumors with complement-activating monoclonal antibodies (mAb) are (i) inherent resistance of tumor cells to complement cytolysis and (ii) a possible undiscriminatory attack against normal cells. In the present study we have developed a procedure to simultaneously direct the complement membrane attack complex and neutralize its inhibitor CD59 (protectin) on human melanoma cells in vitro. G361 melanoma cells were selectively recognized in heterogenous cell mixtures by a complement-fixing mAb (R24) against the tumor cell GD3-ganglioside. Biotinylated anti-CD59 mAb (YTH53.1) was directed to the tumor cells with a high-affinity biotin-avidin bridge using a proportion of R24 as a biotinylated targeting mAb and avidin as a linker. Biotinylated anti-CD59 mAb lost its ability to activate complement, but retained its CD59-neutralizing activity. Thus, it was possible to avoid nonspecific lysis of surrounding erythrocytes and endothelial cells and direct the CD59-neutralizing effect to the tumor cells. As a result the tumor cells were efficiently killed by R24 plus complement while the bystander cells remained viable. These results suggest that it is possible to target an unrestricted complement membrane attack against GD3- and CD59-positive melanoma cells.
Insights
This study developed a method to enhance cancer immunotherapy by targeting melanoma cells with complement-activating monoclonal antibodies (mAb) and neutralizing their resistance. This approach ensures tumor cell destruction while sparing healthy bystander cells.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Monoclonal antibodies (mAb) in cancer immunotherapy face challenges like tumor cell resistance to complement-mediated lysis and potential attacks on normal cells.
- Complement-activating mAb therapy requires overcoming inherent tumor cell resistance and ensuring target specificity.
Purpose of the Study:
- To develop a novel procedure for simultaneously directing the complement membrane attack complex and neutralizing CD59 (protectin) on human melanoma cells in vitro.
- To enhance the efficacy of complement-dependent immunotherapy against melanoma by overcoming tumor cell resistance mechanisms.
Main Methods:
- Utilized a complement-fixing mAb (R24) targeting GD3-ganglioside on G361 melanoma cells for selective recognition.
- Employed a biotinylated anti-CD59 mAb (YTH53.1) linked via a biotin-avidin bridge to R24 to specifically target CD59 on tumor cells.
- Ensured the biotinylated anti-CD59 mAb retained its neutralizing activity against CD59 while losing complement-activating ability to prevent bystander cell lysis.
Main Results:
- The targeted delivery of anti-CD59 mAb effectively neutralized CD59 on melanoma cells.
- Tumor cells (G361 melanoma) were efficiently killed by R24 mAb and complement.
- Surrounding normal cells, including erythrocytes and endothelial cells, remained viable, demonstrating specificity and reduced off-target effects.
Conclusions:
- The developed procedure allows for the simultaneous targeting of complement membrane attack complex and neutralization of CD59 on GD3- and CD59-positive melanoma cells.
- This strategy enables an unrestricted complement membrane attack specifically against tumor cells, overcoming resistance and improving immunotherapy outcomes.
- The findings suggest a promising approach for enhancing the effectiveness and safety of mAb-based cancer immunotherapy.